Table 1

Patient baseline characteristics by study treatment group

	Prior deutetrabenazine (n=232)		Prior placebo (n=111)		All patients (N=343)
Patient demographics and clinical characteristics
	Mean	SE	Mean	SE	Mean	SE
Age (years)	57.6	0.7	54.6	1.1	56.7	0.6
Weight (kg)	82.5	1.4	83.3	1.9	82.8	1.1
TD duration (years)	5.5	0.4	6.1	0.5	5.7	0.3
Baseline total AIMS score	8.8	0.2	8.9	0.4	8.8	0.2
QTcF interval (ms)	412.6	1.7	410.8	2.2	412.0	1.3
	N	%	N	%	N	%
Female	130	56	61	55	191	56
Caucasian	182	78	88	79	270	79
Baseline use of DRA	170	73	86	77	256	75
Typical antipsychotics	15	6	4	4	19	6
Atypical antipsychotics	136	59	77	69	213	62
Both	19	8	5	5	24	7
Background c omorbid i llness
Psychotic disorders	139	60	66	59	205	60
Schizophrenia	116	50	51	46	167	49
Schizoaffective disorder	23	10	15	14	38	11
Mood disorders	93	40	44	40	137	40
Bipolar	35	15	28	25	63	18
Depression	46	20	13	12	59	17
Other	12	5	3	3	15	4

AIMS, Abnormal Involuntary Movement Scale; DRA, dopamine receptor-antagonist; QTcF, Fridericia-corrected QT interval; SE, standard error; TD, tardive dyskinesia.